Piper Jaffray Downgrades Pharmacyclics (PCYC) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pharmacyclics (PCYC) Story Unchanged Following Q1 Report; Roth Reiterates at 'Buy'
May 5, 2014 11:37 AM EDTRoth Capital affirms its Buy rating and $183 target price on Pharmacyclics Inc. (Nasdaq: PCYC) following Q1 results reported last week.
Analyst Joseph Pantginis commented, After PCYC's first full quarter as a commercial stage-company, we are impressed with Imbruvica sales so far. The company provided net product revenue guidance of $80 million for 2Q14 and $295 million for FY14. The company stressed that this is very... More
Pharmacyclics, Inc. (PCYC) Tops Q1 EPS Views; Updates on IMBRUVICA
May 2, 2014 8:04 AM EDTPharmacyclics, Inc. (NASDAQ: PCYC) reported Q1 EPS of $0.40, $0.23 better than the analyst estimate of $0.17. Revenue for the quarter came in at $119.4 million versus the consensus estimate of $105.38 million.
Clinical Update
IMBRUVICA clinical trials are active in all regions including US, Europe, Asia Pacific, Canada and Latin America. Currently IMBRUVICA is being developed in 8 different B-cell malignancies. There are 11 Phase III clinical trials initiated with IMBRUVICA and a total of 43 trials are registered on www.clinicaltrials.gov, of these 21 are... More
Pharmacyclics, Inc. (PCYC) trading halted with news pending
May 2, 2014 7:56 AM EDTPharmacyclics, Inc. (NASDAQ: PCYC) trading halted with news pending.
... More